# Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

> **NCT00492505** · PHASE2 · UNKNOWN · sponsor: **San Diego Pacific Oncology & Hematology Associates** · enrollment: 200 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** cisplatin
- **DRUG:** sorafenib tosylate
- **DRUG:** tamoxifen citrate
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00492505
- **Lead sponsor:** San Diego Pacific Oncology & Hematology Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-04
- **Primary completion:** 2011-12
- **Final completion:** —
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2014-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492505, "Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00492505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*